

AUROBINDO PHARMA LIMITED

Regd. Office: Plot No.2, Mainvihar, Amteerpet, Hyderabad - 500 038, India

Rs. in lakhs

STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2013

PART I	Particulars	Stand alone						Consolidated					
		Three months ended			Nine months ended			Three months ended			Nine months ended		
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013	31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	Year Ended
1	Income from operations	189,291	158,162	141,263	507,031	389,767	535,291	213,552	189,748	155,195	573,260	423,044	578,312
	(a) Net sales/Income from operations (Net of excise duty)	504	1,638	1,874	3,738	5,450	7,219	504	1,638	1,814	3,738	5,450	7,219
	(b) Other operating income	189,795	159,800	143,137	510,769	395,217	542,510	214,056	191,386	157,009	576,998	428,494	585,531
2	Total income from operations (net)	88,028	80,838	85,423	248,425	232,142	305,364	90,294	85,166	84,470	254,153	233,563	309,144
	(a) Cost of material consumed	6,424	429	2,229	8,737	6,138	7,809	9,155	2,838	3,010	17,166	11,456	16,958
	(b) Purchase of stock-in-trade	(4,648)	1,855	(8,873)	2,865	(17,505)	(12,108)	(9,677)	3,917	(9,260)	(498)	(26,410)	(27,025)
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	13,347	11,964	10,995	37,657	32,016	43,142	21,343	19,596	16,682	59,830	48,812	66,331
	(d) Employee benefits expense	4,719	4,703	4,224	14,015	12,541	17,139	7,597	7,662	6,079	22,451	17,946	24,874
	(e) Depreciation and amortisation expense	-	2,500	-	2,500	1,800	6,900	-	-	-	-	-	-
	(f) Provision for decline in the value of long-term investment	28,662	26,185	25,113	79,748	70,118	95,597	38,561	36,034	36,198	107,361	96,173	131,216
	(g) Other expenses	136,532	128,474	119,111	393,947	337,250	463,843	157,273	155,213	137,179	460,463	381,540	521,498
	Total expenses	53,263	31,326	24,026	116,822	57,967	78,667	56,783	36,173	19,830	116,535	46,954	64,033
3	Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	1,313	205	108	1,805	838	1,501	356	511	564	1,259	1,445	2,854
4	Other Income	54,576	31,531	24,134	118,627	58,805	80,168	57,139	36,684	20,394	117,794	48,399	66,887
5	Profit/(Loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)	1,745	1,969	2,850	5,787	8,879	11,474	2,374	2,458	3,312	7,371	9,973	13,133
6	Finance costs (refer note 6)	(2,021)	7,838	6,496	19,770	13,336	12,382	(208)	6,829	7,336	23,862	16,214	16,344
7	Foreign exchange (Gain)/Loss (refer note 6)	54,852	21,724	14,788	93,070	36,590	56,312	54,973	27,397	9,746	86,561	22,212	37,410
8	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	-	-	-	93,070	36,590	56,312	-	-	-	-	-	-
9	Exceptional item	54,852	21,724	14,788	93,070	36,590	56,312	54,973	27,397	9,746	86,561	22,212	37,410
10	Profit/(Loss) from ordinary activities before tax (8-9)	13,036	3,754	360	18,921	3,345	6,713	13,361	4,011	9,100	66,744	18,393	29,139
11	Tax expense/(credit)	41,816	17,970	14,428	74,149	33,245	49,599	41,612	23,386	9,100	66,744	18,393	29,139
12	Net Profit/(Loss) for the period (10-11)	41,816	17,970	14,428	74,149	33,245	49,599	41,612	23,386	9,100	66,744	18,393	29,139
13	Minority Interest	41,816	17,970	14,428	74,149	33,245	49,599	41,612	23,386	9,100	66,744	18,393	29,139
14	Net Profit/(Loss) after taxes and minority interest (12-13)	2,912	2,912	2,911	2,912	2,911	2,912	2,912	2,912	2,912	2,912	2,912	2,912
15	Paid-up Equity Share Capital (Face value Re. 1 per share)	14.36	6.17	4.96	25.46	11.42	17.04	14.34	8.07	3.15	23.04	6.36	10.09
16	Reserves excluding Revaluation Reserve	14.34	6.16	4.96	25.43	11.42	17.02	14.32	8.06	3.15	23.01	6.28	10.09
17	Earnings per share of Re.1/- each (not annualised)												
	(a) Basic												
	(a) Diluted												



PART II

SELECT INFORMATION FOR THE QUARTER & NINE MONTHS ENDED 31.12.2013

Particulars	Three months ended			Nine months ended		Year Ended
	31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013
A						
1 PARTICULARS OF SHAREHOLDING						
Public Shareholding	131,834,694	131,514,694	131,708,307	131,834,694	131,708,307	131,514,844
- Number of Shares	45.27	45.16	45.24	45.27	45.24	45.16
- Percentage of Shareholding						
2 Promoters and promoter group Shareholding						
a) Pledged /Incumbered	34,931,797	33,293,797	35,932,297	34,931,797	35,932,297	37,461,297
- Number of Shares	21.92	20.85	22.54	21.92	22.54	23.46
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)						
- Percentage of Shares (as a % of the total share capital of the company)	12.00	11.43	12.34	12.00	12.34	12.86
b) Non-encumbered	124,444,799	126,402,799	123,480,686	124,444,799	123,480,686	122,235,149
- Number of Shares	78.08	79.15	77.46	78.08	77.46	76.54
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)						
- Percentage of Shares (as a % of the total share capital of the company)	42.73	43.41	42.42	42.73	42.42	41.97

Particulars	Three months ended 31.12.2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	65
Disposed of during the quarter	65
Remaining unresolved at the end of the quarter	Nil



NOTES:

- 1 The above unaudited financial results for the quarter and nine months ended December 31, 2013, as reviewed by the Audit Committee have been approved by the Board at its meeting held on February 06, 2014. A Limited Review of the stand alone financial results for the quarter ended December 31, 2013 has been carried out by the Statutory Auditors.
- 2 The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 ' Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and Joint Venture
- 3 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 4 Sales of standalone for the current quarter include exports Rs. 143,682 lakhs(Quarter ended December 31, 2012: Rs.102,921 lakhs)
- 5 Net sales for the current quarter include dossier income in standalone of Rs.98 lakhs (Quarter ended December 31, 2012:Rs.1,857 lakhs) and in consolidated of Rs.167 lakhs (Quarter ended December 30, 2012: Rs.3,855 lakhs)
- 6 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs.5,196 lakhs, Rs.4,920 lakhs, Rs.4,999 lakhs for three months ended December 31, 2013, September 30, 2013, December 31, 2012, respectively and Rs.15,164 lakhs, Rs.14,444 lakhs for the nine months ended December 31, 2013 and December 31, 2012 respectively and Rs.13,532 lakhs for the year ended March 31, 2013 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of 'AS 16' on Borrowing costs.
- 7 With effect from April 1, 2013, the Company has changed the accounting policy for valuation of cost of the inventory from 'first-in-first-out basis to 'moving average basis'. Accordingly, this has resulted in decrease/(increase) in the value of inventory on standalone basis as at December 31, 2013 and September 30, 2013 by Rs. 377 lakhs and Rs.694 lakhs respectively, and on consolidated basis by Rs.(1786 lakhs) and Rs.713 lakhs respectively, and decrease/(increase) in profit before tax on standalone basis for the quarter ended December 31, 2013 and September 30, 2013, and for the nine months ended December 31, 2013 by Rs.(317 lakhs), Rs.634 lakhs and Rs.377 lakhs respectively, and on consolidated basis for the quarter ended December 31, 2013 and September 30, 2013, and for the nine months ended December 31, 2013 by (Rs.2390 lakhs), Rs.554 lakhs and Rs. (1792 lakhs) respectively.
- 8 The Company incorporated a wholly owned subsidiary viz. AuroZymes Limited on November 28, 2013.
- 9 The Company has allotted 1,27,500 equity shares Re.1/- each under ESOP on January 9, 2014. Consequently, the paid up share capital of the Company has increased to 29,13,38,790 equity shares of Re.1/- each.
- 10 Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

Place: Hyderabad

Date : February 6, 2014

www.aurobindo.com

By Order of the Board

N.Govindarajan

Managing Director

